You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
Comment on ‘Incomplete IUS removal’
  1. Mika Alanko, PhD
  1. Dearbhla Hull, BSc, MBBS
  1. Pirjo Inki, * MD, PhD
  1. Director, Quality Management & HSE, Bayer Oy, Turku, Finland; mika.alanko@bayer.com
  2. Head of Medical Advisory, Women's Health, Bayer Plc, Newbury, UK; dearbhla.hull@bayer.com
  3. Global Medical Lead IUS Family, Global Medical Affairs Women's Health, Bayer HealthCare Pharmaceuticals, Turku, Finland; pirjo.inki@bayer.com
  1. *Corresponding author.

https://doi.org/10.1136/jfprhc-2014-101065

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We would like to respond to the letter to the editor1 from Dr Agarwal that appeared in the July 2014 issue of this Journal.

    Dr Agarwal describes a case where an intrauterine system (IUS) was removed from a 51-year-old patient after it had been in situ for 8 years. Upon removal, it was thought that the transverse arms of the IUS were missing, and the patient subsequently underwent ultrasound and hysteroscopy examination, the latter failing to locate the IUS arms. On ultrasound, it was thought that a linear echogenicity at …

    View Full Text

    Footnotes

    • Competing interests All the authors are employees of Bayer, the pharmaceutical company that manufactures Mirena® and Jaydess® intrauterine systems.